Ramelteon for the treatment of insomnia in menopausal women.
Ramelteon for the treatment of insomnia in menopausal women.
复制标题
DOI：
10.1258/mi.2009.009002
复制
发表时间：
2009-03
期刊：
影响因子：
--
通讯作者：
Gara MA
中科院分区：
文献类型：
--
作者：
Dobkin RD;Menza M;Bienfait KL;Allen LA;Marin H;Gara MA
据报道，睡眠障碍是更年期最令人不安的表现之一。虽然激素替代疗法（HRT）历来被认为是更年期失眠的一线治疗，但由于担心HRT的风险和副作用，许多女性现在正在寻求替代治疗。本研究的目的是评价雷美替恩（一种选择性褪黑素受体激动剂）治疗绝经期失眠的效果。共有20名健康的绝经期和绝经后失眠妇女参加了在一个学术医学中心进行的为期六周的雷美替恩（8毫克）前瞻性开放标签试验。参与者每天完成睡眠-觉醒日记，持续6周。睡眠障碍，白天功能，生活质量和情绪的自我报告措施也完成了两周一次。在日记数据中观察到入睡潜伏期、总睡眠时间和睡眠效率的显著改善，而在自我报告测量中发现睡眠质量、睡眠障碍、日间功能、生活质量和情绪的改善。在试验过程中没有耐受性或反弹的证据。总体而言，结果表明，雷美琼是一种有效的非激素治疗更年期失眠的方法。需要随机对照试验来进一步评估这种干预措施的有效性。
Sleep disturbances have been reported to be one of the most troubling manifestations of menopause. While hormone replacement therapy (HRT) has historically been considered a first-line treatment for menopausal insomnia, many women are now seeking alternatives treatments due to concerns about the risks and side-effects of HRT. The goal of this study was to evaluate the effect of ramelteon, a selective melatonin receptor agonist, for the treatment of menopausal insomnia. A total of 20 healthy peri and postmenopausal women with insomnia participated in this six-week, prospective, open-label trial of ramelteon (8mg) at an academic medical center. Participants completed sleep-wake diaries on a daily basis for 6-weeks. Self-report measures of sleep impairment, daytime functioning, quality of life, and mood were also completed on a bi-weekly basis. Significant improvements in latency to sleep onset, total sleep time, and sleep efficiency were observed in diary data while gains in sleep quality, sleep impairment, daytime functioning, quality of life, and mood were found on self-report measures. There was no evidence of tolerance or rebound over the course of the trial. Overall, results suggest that ramelteon is an effective non-hormonal approach for the treatment of insomnia in menopause. Randomized controlled trials are needed to further evaluate the efficacy of this intervention.